Gold climbed to an all-time high as a weaker dollar and rising odds of a U.S. government shutdown drove investors into defensive assets. The move underscores market anxiety heading into a pivotal week for economic data and fiscal negotiations, with energy and rate volatility adding to cross-asset hedging demand.
Source: Seeking Alpha
Bonds in the spotlight: Jobs data could reprice Fed-cut timeline
U.S. Treasuries are poised for a critical week as investors await labor-market data to gauge the Federal Reserve’s path after recent wavering in rate-cut bets. A hotter or cooler print could swing front-end yields and curve positioning, with knock-on effects for equities and credit risk appetite.
Source: Seeking Alpha
SEC fast-tracks plan to end quarterly reporting, jolting disclosure landscape
SEC Chair Paul Atkins is moving quickly on President Trump’s proposal to eliminate quarterly reporting, setting up a potential overhaul of corporate disclosure cadence. Proponents argue fewer reports would curb short-termism; critics warn reduced transparency could heighten volatility and impair price discovery.
Source: Seeking Alpha
OPEC+ weighs another output hike in November
OPEC+ is considering a fresh production increase next month, testing crude’s recent strength against growth concerns and inventory dynamics. Any supply adjustment will ripple through inflation expectations, energy equities, and import-dependent economies heading into year-end.
Source: Seeking Alpha
Occidental in talks to sell petrochem unit for $10B to streamline portfolio
Occidental Petroleum is negotiating a roughly $10 billion sale of its petrochemical business, the Financial Times reported, in a move that could sharpen its focus on core oil and low-carbon initiatives. Proceeds would bolster the balance sheet and potentially fund capex or shareholder returns as M&A and asset rotations pick up across energy.
Source: Seeking Alpha
GSK taps insider Luke Miels as next CEO; shares rally on continuity bet
GSK named current COO Luke Miels as chief executive, a succession that investors read as continuity for execution on vaccines and specialty medicines. The stock advanced on expectations of steady strategy and pipeline delivery amid a busy biopharma dealmaking backdrop.
Source: Seeking Alpha
Goldman: Positioning still light even as IPOs and M&A surge
Despite mounting chatter about froth, Goldman Sachs says investor risk exposure remains relatively subdued while primary markets re-open and deal activity accelerates. The combination suggests the rally’s leadership could broaden if cash on the sidelines is redeployed into equities and credit.
Source: Seeking Alpha
You May Also Be Interested In...
Wall Street eyes new leaders beyond the Magnificent Seven as AI trade expands
Stock index futures climb as focus shifts to potential government shutdown
Trump to host congressional leaders as shutdown deadline looms
Goldman’s 48 potential M&A candidates
TotalEnergies to sell 50% stake in North American solar portfolio
Genmab reportedly nearing deal to acquire cancer drug developer Merus
Walmart warns AI will reshape every job, pledges to retrain workers
Democrats push back on leverage relief as a fix for the Treasury market